Table 1 Main characteristics of the studies included in the meta-analysis
Study | Year | Study design | N | Age | Cancer type | Data type | Reference standard | Follow-up time | PET/MRI | PET/CT |
|---|---|---|---|---|---|---|---|---|---|---|
Ohno Y [2] | 2015 | Prosp | 140 | 47–83 | Lung cancer | Patient-based | Pathology and imaging follow-up |  ≥ 6 months | 3.0 T -shiba Sequential CE: yes | Dose: 3.3 MBq/Kg Uptake time: 60 min |
Heusch P [2] | 2015 | Retro | 73 | 21–85 | Various cancers | Patient-based | Pathology and imaging follow-up | 273 days (median) | 3.0 T Siemens Simultaneous CE: yes | Dose: 295 MBq(mean) Uptake time: 141 min(mean) |
Lee SM [4] | 2016 | Prosp | 45 | 35–79 | Lung cancer | Patient-based | Pathology and imaging follow-up | 393 days (median) | 3.0 T Siemens Simultaneous CE: yes | Dose: 5.2 MBq/Kg Uptake time: 60 min |
Melsaether AN [5] | 2016 | Prosp | 51 | 32–76 | Breast cancer | Patient & lesion-based | Pathology and imaging follow-up |  ≥ 6 months | 3.0 T Siemens Simultaneous CE: yes | Dose: 547.6 MBq (mean) Uptake time:131 min |
Huellner MW [6] | 2016 | Prosp | 42 | 35–89 | Lung cancer | Patient-based | Pathology and imaging follow-up | 568 days (mean) | 3.0 T GE Sequential CE: none | Dose: 350 MBq Uptake time: 60 min |
Sekine T [7] | 2017 | Prosp | 43 | 20–86 | Occult tumors | Patient-based | Pathology and imaging follow-up | 523–1848 days | 3.0 T GE Sequential CE: 19 patients | Dose: 2 MBq/Kg Uptake time: 69 min(mean) |
Catalano OA [8] | 2017 | Retro | 51 | 20–71 | Breast cancer | Patient-based | Pathology and imaging follow-up |  ≥ 24 months | 3.0 T Siemens Simultaneous CE: yes | Dose: 4.44 MBq/kg Uptake time:60 min |
Ohno Y [9] | 2017 | Prosp | 64 | 56(mean) | Thymic epithelial tumor | Patient-based | Pathology and imaging follow-up |  ≥ 6 months | 3.0 T Canon Sequential CE: yes | Dose: 132–300 MBq Uptake time:60 min |
Botsikas D [10] | 2019 | Prosp | 80 | 48(mean) | Breast cancer | Patient & lesion-based | Pathology and imaging follow-up |  ≥ 12 months | 3.0 T Philips Sequential CE: yes | Dose: 3.5 MBq/kg Uptake time: 60 min |
Ohno Y [11] | 2019 | Prosp | 23 | 55–75 | Malignant pleural mesothelioma | Patient-based | Pathology and imaging follow-up | 6 or 12 months | 3.0 T Canon Sequential CE: yes | Dose: 132–300 MBq Uptake time:60 min |
Liu Y [12] | 2019 | Prosp | 30 |  ≥ 18 | Gastric Cancer | Patient-based | Pathology and imaging follow-up | 3.2–40.7 months | 3.0 T Siemens Simultaneous CE: none | Dose: 2.22—4.44 MBq /kg Uptake time: 20–30 min |
Yeh CH [13] | 2020 | Prosp | 198 | 56(mean) | Pharynx squamous cell carcilowma | Patient & lesion-based | Pathology and imaging follow-up |  ≥ 12 months | 3.0 T Siemens Simultaneous CE: yes | NR |
Ohno Y [14] | 2020 | Prosp | 104 | 43–85 | Lung cancer | Patient-based | Pathology and imaging follow-up |  ≥ 24 months | 3.0 T canon, 1.5 T Philips Sequential CE: yes | Dose: 3.3 MBq/kg Uptake time: 60 min |
Ohno Y [15] | 2021 | Prosp | 98 | 47–83 | Lung cancer | Patient-based | Pathology and imaging follow-up |  ≥ 6 months | 3.0 T Vantage Titan and Galan Sequential CE: yes | NR |